Clavister could provide cybersecurity to Thales' SOTAS communication system A tangible revenue case ...
Q2 report due 15 August '24e-'26e EBITA down 5-1%; 9% CAGR '23-'26e 10-6x EBITA '24e-'26e, 11-15% FC...
Redeye provides a research update on Faron Pharmaceuticals following the outcome of the company’s re...
Biovica records IVD test sales in Q4, which are higher than Q1-Q3, and research test sales have incr...
Redeye comments on the news that the company’s complementary clinical study TRIAC II, which focused ...
Redeye comments on Artificial Solutions' directed rights issue, which was announced after the market...
Niche heat pump OEM with high growth potential Return to positive margins FY'25/26e 10-5x EBIT '25e-...
Redeye comments on Verve’s acquisition of Jun Group, which strengthens its position on the demand si...
The company changed its strategy and abandons its plans to build 600MW of own wind power capacity.
CoinShares International (CS) is a pioneer and a well-established player in the nascent, high-growth...
Redeye comments on Curasight announced financing solution.
Marknadens nedgång träffar till slut med full kraft, så ledningen revar seglen och vi sänker prognos...
Q2 report due 18 July We forecast SEK 561m net sales, SEK 81m EBITA Fair value range raised to SEK 4...
Redeye expects a Q2 report from Addnode with limited organic growth yet solid margins.
2024 likely to be back-end loaded Company still expects 3-5 more design wins in 2024 Guidance implie...
Analyst Group har med Refine Group ingått avtal om kontinuerlig analysbevakning, innefattande bl.
Redeye leaves a comment following Lipum’s announcement of further clinical advancements in the ongoi...
Vultus AB (publ) (”Vultus” eller ”Bolaget”) erbjuder marknadsledande tjänster, vilket inkluderar fjä...
Redeye is encouraged by the news that Kontigo Care is launching Previct Safety—a digital drug test s...
